tirzepatide uptodate (LY3298176) is a Dual GIP and GLP-1 Receptor Agonist for Type 2 Diabetes Research Tirzepatide vs. Retatrutide: Key Differences
Description
Some patients experience increased bowel frequency or looser stools, particularly during the initial weeks of treatment or after dose escalation
This approach maximizes initial results while minimizing long-term injection burden
These powerful medications offer a range of benefits for individuals seeking to lose weight and improve their metabolic health
Semaglutide: single receptor, proven pathway Semaglutide is a GLP-1 receptor agonist
